Chardan Capital reiterated coverage on Durect with a new price target

2/3/21 8:15:53 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

Chardan Capital reiterated coverage of Durect with a rating of Buy and set a new price target of $8.00 from $7.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$DRRX

Date	Price Target	Rating	Analyst